作为首款且唯一国内自主研发的质子泵抑制剂，安久卫于2023年6月在中国获批上市，用于治疗十二指 肠溃疡，并于2023年12月首次纳入国家基本医保药品目录。本次安久卫成功续约2025年国家基本医保药 品目录，将利于稳定市场销售，继续惠及更多患者人群，提升该产品在相关适应症上的渗透率，为安久 卫的长期增长注入动力。 四环医药(00460)发布公告，经过与国家医保局的简易医保续约，集团旗下非全资附属公司轩竹生物科 技股份有限公司自主研发的创新药安奈拉唑钠肠溶片(商品名：安久卫)将继续获纳入自2026年1月1日起 生效的新版《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(2025年国家基本医保药品目 录)。 ...

Core Viewpoint - XuanZhu Bio-B (02575) has successfully renewed the inclusion of its innovative drug Annelazole Sodium Enteric-Coated Tablets (brand name: Anjiuwei) in the new National Basic Medical Insurance Drug List (2025) effective from January 1, 2026, following negotiations with the National Healthcare Security Administration [1] Group 1 - Anjiuwei is the first and only domestically developed proton pump inhibitor in China, approved for market launch in June 2023 for the treatment of duodenal ulcers [1] - The drug was first included in the National Basic Medical Insurance Drug List in December 2023, which is expected to stabilize market sales and benefit a larger patient population [1] - The successful renewal of Anjiuwei's inclusion in the 2025 National Basic Medical Insurance Drug List is anticipated to enhance its penetration rate in relevant indications, providing momentum for long-term growth [1]